Department of Pharmacy (DiFAR), University of Genoa, Viale Cembrano 4, I-16148 Genova, Italy.
Int J Mol Sci. 2023 Jun 6;24(12):9824. doi: 10.3390/ijms24129824.
The awareness of the existence of plant bioactive compounds, namely, phytochemicals (PHYs), with health properties is progressively expanding. Therefore, their massive introduction in the normal diet and in food supplements and their use as natural therapeutics to treat several diseases are increasingly emphasized by several sectors. In particular, most PHYs possessing antifungal, antiviral, anti-inflammatory, antibacterial, antiulcer, anti-cholesterol, hypoglycemic, immunomodulatory, and antioxidant properties have been isolated from plants. Additionally, their secondary modification with new functionalities to further improve their intrinsic beneficial effects has been extensively investigated. Unfortunately, although the idea of exploiting PHYs as therapeutics is amazing, its realization is far from simple, and the possibility of employing them as efficient clinically administrable drugs is almost utopic. Most PHYs are insoluble in water, and, especially when introduced orally, they hardly manage to pass through physiological barriers and scarcely reach the site of action in therapeutic concentrations. Their degradation by enzymatic and microbial digestion, as well as their rapid metabolism and excretion, strongly limits their in vivo activity. To overcome these drawbacks, several nanotechnological approaches have been used, and many nanosized PHY-loaded delivery systems have been developed. This paper, by reporting various case studies, reviews the foremost nanosuspension- and nanoemulsion-based techniques developed for formulating the most relevant PHYs into more bioavailable nanoparticles (NPs) that are suitable or promising for clinical application, mainly by oral administration. In addition, the acute and chronic toxic effects due to exposure to NPs reported so far, the possible nanotoxicity that could result from their massive employment, and ongoing actions to improve knowledge in this field are discussed. The state of the art concerning the actual clinical application of both PHYs and the nanotechnologically engineered PHYs is also reviewed.
植物生物活性化合物(即植物化学物质,PHYs)具有健康属性,人们对其存在的认识正在逐步扩大。因此,越来越多的人强调将其大量引入正常饮食和食品补充剂中,并将其用作治疗多种疾病的天然疗法。特别是,大多数具有抗真菌、抗病毒、抗炎、抗菌、抗溃疡、降胆固醇、降血糖、免疫调节和抗氧化特性的 PHYs 已从植物中分离出来。此外,还广泛研究了对其进行二次修饰以进一步提高其内在有益作用的新功能。不幸的是,尽管利用 PHYs 作为治疗剂的想法令人惊叹,但实现这一目标远非易事,并且将它们用作有效临床可管理药物的可能性几乎是乌托邦式的。大多数 PHYs 不溶于水,特别是当口服引入时,它们几乎无法通过生理屏障,并且很难在治疗浓度下到达作用部位。它们在酶和微生物消化过程中的降解以及它们的快速代谢和排泄强烈限制了它们的体内活性。为了克服这些缺点,已经使用了几种纳米技术方法,并且已经开发了许多载有纳米 PHY 的纳米级递送系统。本文通过报道各种案例研究,综述了为将最相关的 PHYs 制成更具生物利用度的纳米颗粒(NPs)而开发的最先进的基于纳米悬浮液和纳米乳液的技术,这些 NPs 适合或有望通过口服进行临床应用。此外,还讨论了迄今为止因暴露于 NPs 而报告的急性和慢性毒性作用、可能由于其大量使用而导致的纳米毒性以及正在采取的措施以提高该领域的知识水平。还综述了 PHYs 和通过纳米技术工程化的 PHYs 的实际临床应用的现状。